Background {#Sec1}
==========

Tuberculosis (TB) is a major infectious disease of global proportions. According to the annual surveys conducted by World Health Organization (WHO), an estimated 10 million new active TB diseases cases and 1.6 million deaths occurred in 2017, making TB as the leading cause of death from a single infectious agent \[[@CR1]\]. Near 87% of all TB cases occurred in 30 high-TB-burden countries with nearly 67% of all cases occurring in only eight (India, China, Indonesia, Philippines, Pakistan, Nigeria, Bangladesh and South Africa) countries. In high-TB-burden countries, active TB disease cases usually occur as a result of recent infection or reinfection while in low-TB-incidence countries, most active disease cases occur as a result of reactivation of latent infection acquired few to several years earlier \[[@CR2]--[@CR4]\]. Most of the TB deaths recorded in recent years have been attributed to drug-resistant (DR) TB \[[@CR1]\]. Worldwide, 558,000 people developed TB in 2017 that was resistant to rifampicin, and of these, nearly 457,000 (82%) were inflicted with *Mycobacterium tuberculosis* strains resistant at least to rifampicin and isoniazid, the two most effective first-line drugs (MDR-TB) \[[@CR1]\]. The MDR-TB in resource-limited settings is difficult to treat due to lengthy, more expensive and more toxic treatment regimens which lead to higher rates of clinical failure and disease relapse \[[@CR5], [@CR6]\]. MDR-TB is also a risk factor for the development of extensively drug-resistant TB (XDR-TB), infection with MDR-TB strains additionally resistant to a fluoroquinolone and an injectable anti-TB drug, which is even more difficult to treat than MDR-TB \[[@CR1], [@CR5], [@CR6]\]. Globally, treatment success rates for fully susceptible TB, MDR-TB and XDR-TB have been estimated as nearly 95%, 55% and 28%, respectively \[[@CR1]\]. Rapid and accurate laboratory diagnosis of MDR-TB is crucial for effective treatment, which will also limit further transmission of MDR-TB and evolution of XDR-TB \[[@CR1], [@CR5]\].

The evolution of drug resistance in clinical *M. tuberculosis* strains is mainly due to chromosomal mutations in target genes \[[@CR5], [@CR7]\]. The WHO now recommends that drug susceptibility testing (DST) of *M. tuberculosis* isolates should be carried out for all patients with TB to guide treatment decisions and to improve outcome \[[@CR1]\]. Phenotypic DST methods are time-consuming as they require several days to few weeks to report results and are also not widely available \[[@CR8]\]. Recent studies have shown that gene sequencing studies reliably predict susceptibility or resistance to first-line anti-TB drugs and are even superior to phenotypic-based DST methods for some first-line drugs \[[@CR9]--[@CR13]\].

Kuwait, an Arabian Gulf country in the Middle East, is a low TB incidence (\~ 24 cases/100 000 population) country \[[@CR14], [@CR15]\]. The expatriates account for nearly 75% of the total population of Kuwait. Although all expatriates are screened at the time of entry into Kuwait for the absence of active TB disease, \> 80% of all TB cases and \> 95% of DR-TB and MDR-TB cases occur among expatriate patients, mainly originating from TB endemic countries of South Asia (Bangladesh, India, Pakistan, etc.), Southeast Asia (mainly Philippines and Indonesia) and Africa \[[@CR16]--[@CR19]\]. The diversity of mutations and fingerprinting profiles among multidrug-resistant *M. tuberculosis* isolates have previously shown that most expatriate patients developed active disease in Kuwait due to reactivation of previously acquired infection \[[@CR17], [@CR18]\]. Until recently, rifampicin-resistant TB/MDR-TB among Kuwaiti subjects were infrequently detected \[[@CR16]--[@CR19]\] and transmission of DR-TB was rarely reported in Kuwait \[[@CR20]\]. A fourfold increase in the detection of MDR-TB among Kuwaiti subjects was noted in recent years (2014--2017); however, the factors responsible for this sudden increase remained unknown and transmission of MDR-TB within Kuwait was not apparent from routine surveillance studies. This study performed detailed molecular characterization of all MDR-TB strains collected during a 12-year period (2006 to 2017) to detect mutations in seven major gene targets (*rpoB*, *katG*, *inhA*, *pncA, embB, rpsL* and *rrs*) conferring resistance to rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin. Fingerprinting of all isolates was performed by spoligotyping. The sequence data obtained from multiple loci were also used to generate phylogenetic tree to ascertain strain relatedness (multi-locus sequence analysis, MLSA). Data from spoligotyping and MLSA were combined to define cluster(s) of isolates possibly reflecting local transmission of infection within Kuwait. Sequence data for two additional loci (*gidB* and *rpsA*) known to carry phylogenetic polymorphisms \[[@CR21], [@CR22]\] were also obtained for cluster isolates obtained within a short time frame (nearly 2 years) to confirm their close genetic relatedness.

Methods {#Sec2}
=======

Patients, specimens and *M. tuberculosis* isolates {#Sec3}
--------------------------------------------------

A total of 93 multidrug-resistant *M. tuberculosis* (MDR-TB) strains obtained from 93 suspected TB patients during 2006 to 2017 and 50 drug-susceptible *M. tuberculosis* isolates collected from 50 TB patients were analyzed in this study. The MDR-TB strains were cultured from 74 pulmonary and 19 extra-pulmonary specimens at Kuwait National TB Control Laboratory (KNTCL). All clinical specimens were collected from suspected TB patients before initiation of treatment with anti-TB drugs and after obtaining verbal consent as part of routine patient care, diagnostic workup and resistance surveillance. All specimens were cultured on solid (Lowenstein-Jensen) and liquid (mycobacteria growth indicator tube, MGIT 960 system) media according to manufacturer's instructions (Becton Dickinson, Sparks, MD, USA) and as described previously \[[@CR14], [@CR23]\]. Repeat isolates typically cultured within 1 week of isolation of the first isolate were also available from 35 patients yielding MDR-TB strains. The MGIT 960 system cultures were analyzed at Reference Mycobacteriology Laboratory, Department of Microbiology, Faculty of Medicine, Kuwait University, and the results are reported in this paper anonymously, without revealing patient identity.

Non-sterile samples were processed by using *N*-acetyl-[l]{.smallcaps}-cysteine and sodium hydroxide (NALC/NaOH), while sterile clinical specimens were processed directly for the cultivation of mycobacteria, as described previously \[[@CR14], [@CR23]\]. All samples yielded a positive growth reading in MGIT 960 system cultures, and all MGIT cultures were positive for the presence of acid-fast bacilli by Ziehl-Neelsen smear microscopy and for *M. tuberculosis* complex DNA by AccuProbe DNA probe assay and by an in-house multiplex PCR assay, performed as described previously \[[@CR23], [@CR24]\].

Phenotypic drug susceptibility testing {#Sec4}
--------------------------------------

All *M. tuberculosis* isolates were subjected to phenotypic DST against rifampicin, isoniazid, ethambutol and streptomycin by using Bactec 460 TB system (for isolates collected during 2006--2010) or MGIT 960 system (for isolates collected during 2011--2017) using SIRE drug kit, according to the manufacturer's recommendations and as described in detail previously \[[@CR14], [@CR23]\]. The DST against pyrazinamide (PZA) was also performed for the isolates by using MGIT 960 system and the MGIT 960 PZA kits according to the manufacturer's instructions (Becton Dickinson).

Molecular characterization for detection of mutations predicting resistance {#Sec5}
---------------------------------------------------------------------------

Genomic DNA was extracted from each MGIT culture by the rapid Chelex-100 method as described in detail previously \[[@CR25]\]. The MDR-TB status of all isolates was tested by the GenoType MTBDR*plus* line probe assay, performed as described previously \[[@CR26]\]. The results were confirmed and extended by PCR amplification followed by DNA sequencing (PCR sequencing) of three (hot spot, N-terminal and cluster II) regions of *rpoB* gene, *katG* codon 315 (*katG315*) and *inhA* regulatory region (*inhA*-RR) by using gene-specific PCR (Additional file [1](#MOESM1){ref-type="media"}: Table S1) and sequencing (Additional file [2](#MOESM2){ref-type="media"}: Table S2) primers and as described previously \[[@CR26]\]. For isolates with wild-type sequence for *katG315* and *inhA*-RR, the extended N-terminal regions of *katG* and *inhA* were sequenced by using gene-specific PCR (Additional file [1](#MOESM1){ref-type="media"}: Table S1) and sequencing (Additional file [2](#MOESM2){ref-type="media"}: Table S2) primers. The molecular basis of resistance to ethambutol, streptomycin and pyrazinamide was also determined, as described previously, by PCR sequencing of *embB306* + *embB406* + *embB497* regions \[[@CR27], [@CR28]\], *rpsL* + *rrs* (500 and 900 regions) \[[@CR28]\] and *pncA* gene \[[@CR12], [@CR29]\], respectively, by using gene-specific PCR (Additional file [1](#MOESM1){ref-type="media"}: Table S1) and sequencing (Additional file [2](#MOESM2){ref-type="media"}: Table S2) primers. The sequence data for *rpoB*, *katG*, *inhA*, *pncA*, *embB*, *rpsL* and *rrs* loci obtained for each isolate were concatenated and the combined sequence data were used to construct phylogenetic tree by using the unweighted pair group method with arithmetic averages (UPGMA) settings by using MEGA7 software. A cluster was defined when two or more patient isolates shared the same sequence profile for all seven loci.

Spoligotyping {#Sec6}
-------------

All MDR-TB isolates were also subjected to spoligotyping, performed as described previously \[[@CR30]\]. The results in binary format were used for assignment of phylogenetic lineages according to SITVIT database (http://www.pasteur-guadeloupe.fr.:8081/SITVITDemo/index.jsp). The spoligotype-based dendrogram was generated by UPGMA calculation using MIRU-VNTRplus web page (<http://www.miru-vntrplus.org>). A cluster was defined when two or more patient isolates shared same spoligotype pattern. Spoligotype patterns not described in SITVIT2 database were designated as 'orphan' \[[@CR31]\].

Further molecular analysis of cluster isolates {#Sec7}
----------------------------------------------

PCR sequencing of *gidB* and *rpsA*, *M. tuberculosis* targets that may confer resistance to streptomycin and pyrazinamide, respectively, and known to carry lineage-specific polymorphisms \[[@CR21], [@CR22], [@CR32]\] was also carried out for isolates clustered by both (multi-gene sequence data and spoligotyping data) fingerprinting methods and were obtained from TB patients within a 2-year period by using gene-specific PCR (Additional file [2](#MOESM2){ref-type="media"}: Table S1) and sequencing (Additional file [2](#MOESM2){ref-type="media"}: Table S2) primers and the PCR amplification and sequencing protocols described previously \[[@CR23], [@CR26]\]. Additional file [1](#MOESM1){ref-type="media"}: Table S1 showing primer sequences for PCR amplification while Additional file [2](#MOESM2){ref-type="media"}: Table S2 showing primer sequences used for DNA sequencing of various gene loci.

Statistical analysis {#Sec8}
--------------------

Categorical variables were expressed as absolute number. Statistical analysis was performed using Pearson's Chi square test and probability levels \< 0.05 were considered as statistically significant. Statistical analyses were performed by using WinPepi software ver. 11.65 (PEPI for Windows, Microsoft Inc., Redmond, WA, USA).

Results {#Sec9}
=======

Characteristics of *M. tuberculosis* isolates {#Sec10}
---------------------------------------------

A total of 93 MDR-TB strains obtained from 93 TB patients during 2006 to 2017 (representing all available MDR-TB strains collected during this period) and 50 fully susceptible *M. tuberculosis* isolates collected from 50 TB patients were used. The MDR-TB strains were cultured from 74 pulmonary (sputum, *n* = 66 and bronchoalveolar lavage, *n* = 8) and 19 extra-pulmonary (fine needle aspirate, *n* = 8; pus, *n* = 5; tissue biopsy, *n* = 3; lymph node, *n* = 2 and cerebrospinal fluid, *n* = 1) specimens obtained from 12 Kuwaiti and 81 expatriate (Indian, *n* = 35; Ethiopian, *n* = 15; Filipino, *n* = 13; Iraqi, *n* = 4; Nepalese, *n* = 4; Egyptian, *n* = 3; Bangladeshi, *n* = 2; Indonesian, *n* = 2; Syrian, *n* = 1; Saudi Arabian, *n* = 1 and Georgian, *n* = 1) patients (males *n* = 49; females, *n* = 44). All isolates were cultured from newly diagnosed TB patients before initiation of treatment with anti-TB drugs. Prior treatment history was not available for expatriate TB patients.

The 50 drug-susceptible *M. tuberculosis* isolates were susceptible to all four (rifampicin, isoniazid, ethambutol and streptomycin) drugs tested (pansusceptible strains). All 93 drug-resistant isolates were uniformly resistant to rifampicin and isoniazid (MDR-TB strains). Forty-one isolates were additionally resistant to ethambutol while 59 isolates were additionally resistant to streptomycin (Table [1](#Tab1){ref-type="table"}). Although all 93 MDR-TB isolates were tested for susceptibility to pyrazinamide, only 47 isolates yielded interpretable results; 11 isolates were susceptible, and 36 were resistant to this drug including 15 isolates that were resistant to all five drugs. The remaining 46 MDR-TB strains failed to grow at the reduced pH in the absence of the drug. No resistance-conferring mutation was detected in any of the seven target genes/gene fragments in any of the 50 pansusceptible strains analyzed in this study. The proportion of MDR-TB isolates exhibiting resistance-conferring mutations in target genes varied for different anti-TB drugs, being highest for rifampicin and lowest for streptomycin (Table [1](#Tab1){ref-type="table"}). Compared to rifampicin, the differences were statistically significant for ethambutol (*P* = 0.008) and streptomycin (*P* = 0.000). Repeat MDR-TB isolates, cultured from 35 patients within 1 week of isolation of the first isolate, yielded the same resistance and mutation patterns as the first isolate from each patient.Table 1Phenotypic resistance by MGIT 960 system to anti-TB drugs among 93 multidrug-resistant *M. tuberculosis* isolates and number of susceptible and resistant isolates with mutations in target genes for each drugAnti-tuberculosisNo. of isolatesNo. of susceptibleNo. of susceptibleNo. of resistantNo. (%) of resistantDrugTestedIsolatesIsolates with mutation^a^IsolatesIsolates with mutation^a^Rifampicin93009393 (100)Isoniazid93009392 (98.9)Pyrazinamide471103630 (83.3)Ethambutol935238^b^4138 (92.7)Streptomycin933405949 (83.1)^a^Resistance-conferring mutations were detected in *rpoB* for rifampicin, *katG* + *inhA* for isoniazid, *pncA* for pyrazinamide, *embB* for ethambutol, and *rpsL* + *rrs* for streptomycin^b^*Mycobacterium tuberculosis* isolates with *embB* mutations usually confer low level of resistance to ethambutol which are often missed by the MGIT 960 system \[[@CR23], [@CR28]\]

Molecular detection of mutations predicting resistance in MDR-TB strains {#Sec11}
------------------------------------------------------------------------

The combination of GenoType MTBDR*plus* assay and PCR sequencing of *rpoB*, *katG* and *inhA* identified *rpoB* mutations (S456L, *n* = 66; H451Y, *n* = 6, D441V, *n* = 4; H451D, *n* = 3; S456W, *n* = 3; Q438K, *n* = 2; V176F, *n* = 2; Q438E, *n* = 1; Q438P, *n* = 1; H451R, *n* = 1; M440I + D441Y, *n* = 2 and D441V + H451Q, *n* = 1) in all 93 isolates and *katG* and *inhA* mutations in 92 (*katG* S315T, *n* = 74; *inhA*-RR −15 C/T, *n* = 11; *katG* S315T + *inhA*-RR −15 C/T, *n* = 3; *katG* S315N, *n* = 1; *inhA* S94A, *n* = 1; *katG* S315T + *inhA*-RR −8 T/A, *n* = 1 and *katG* S315T + *inhA*-RR −17 G/T, *n* = 1) of 93 isolates. The occurrence of the most common *rpoB* (S456L) mutation was nearly same in MDR-TB strains resistant to only two drugs (18 of 27) versus three drugs (24 of 32) (*P* = 0.481) or versus all four SIRE drugs (24 of 34) (*P* = 0.743). The occurrence of S315T mutation in *katG* was significantly lower in MDR-TB strains resistant to two drugs versus isolates resistant to three drugs (19 of 27 versus 29 of 32, *P* = 0.047) as well as versus isolates resistant to all four drugs (19 of 27 versus 31 of 34, *P* = 0.036). On the contrary, the occurrence of *inhA*-RR −15 C/T mutation alone was significantly higher in MDR-TB strains resistant to two drugs versus isolates resistant to three drugs (7 of 27 versus 2 of 32, *P* = 0.036) as well as versus isolates resistant to all four drugs (7 of 27 versus 2 of 34, *P* = 0.028).

PCR sequencing of *pncA* identified mutations in 30 of 36 MDR-TB strains phenotypically resistant to pyrazinamide and 23 of 46 isolates for which phenotypic DST data for pyrazinamide was not available while all 11 isolates phenotypically susceptible to pyrazinamide contained wild-type sequence for *pncA*. The *pncA* mutations included −11 A/G (*n* = 13), non-synonymous mutations (*n* = 28) spread over 19 codon positions; insertion frame shift mutations (*n* = 6); insertion of GGT at nucleotide 390 (*n* = 1); deletion frame shift mutation (*n* = 1); premature termination at codon 111 (*n* = 1); −7 T/C (*n* = 1); −15 A/C + V130A (*n* = 1) and conversion of initiation codon ATG to CTG (*n* = 1). Synonymous mutations (TCC65TCT, *n* = 15 and TCC65TCG, *n* = 2) considered as phylogenetic markers were also identified in 17 isolates.

As reported earlier \[[@CR23], [@CR28]\], *embB* mutations were detected in both ethambutol-resistant and ethambutol-susceptible MDR-TB strains (Table [1](#Tab1){ref-type="table"}). Fifty isolates contained mutations at *embB306* (M306V, *n* = 28; M306I, *n* = 19 and M306L, *n* = 3), 15 isolates contained a mutated *embB406* (G406D, *n* = 8; G406A, *n* = 4; G406C, *n* = 2 and G406S, *n* = 1), 10 isolates contained a mutated *embB497* (Q497R, *n* = 6; Q497K, *n* = 3 and Q497H, *n* = 1) and one isolate contained a mutation (Y319S) at *embB319*. Other mutations (L355L, CTG355CTA + E378A, GAG378GCG, *n* = 3 and E378A, *n* = 2) considered as phylogenetic markers not related with resistance to ethambutol \[[@CR28]\] were also identified in five isolates. Forty-nine of 59 MDR-TB strains additionally resistant to streptomycin contained a mutation in the target genes analyzed (Table [1](#Tab1){ref-type="table"}), many of which have been described previously \[[@CR23], [@CR28]\]. These included 44 isolates with a mutation in *rpsL* (K43R, *n* = 33; K43T, *n* = 1; K88R, *n* = 5; K88T, *n* = 4; K88M, *n* = 1), four isolates with a mutation in *rrs* 500 or 900 region (A514C, *n* = 1; C517T, *n* = 1; G878A, *n* = 1 and A906G, *n* = 1) and one isolate with *rpsL* K88R + *rrs* C602A double mutation.

Spoligotyping analyses {#Sec12}
----------------------

Initial fingerprinting performed by spoligotyping showed that 82 of 93 MDR-TB strains belonged to specific shared international type (SIT), while 11 isolates showed nine unique (orphan) patterns that were not found in SITVIT2 database. The dendrogram generated from the spoligotyping data showed that 18 isolates exhibited unique patterns while 75 isolates grouped in 17 clusters with each cluster containing 2--30 isolates (Fig. [1](#Fig1){ref-type="fig"}). The SIT1 pattern was most common (*n* = 30), and Beijing was the most common family shared among 32 isolates. The occurrence of Beijing genotype was significantly higher in MDR-TB strains resistant to all four drugs versus isolates resistant to two drugs (18 of 34 versus 4 of 27, *P* = 0.002) but not versus isolates resistant to three drugs (18 of 34 versus 10 of 32, *P* = 0.075). Interestingly, 10 of 12 Kuwaiti patients were infected with Beijing genotype.Fig. 1The dendrogram generated from the spoligotyping data using MIRU-VNTRplus database and unweighted pair group method with arithmetic mean (UPGMA) settings for 93 multidrug-resistant *M. tuberculosis* isolates from Kuwait is shown. The nationality of the TB patient yielding the isolate, shared international type (SIT), *M. tuberculosis* family (Family) and the actual spoligotyping patterns for each isolate are shown in vertical columns

Fingerprinting based on multi-locus sequence analysis {#Sec13}
-----------------------------------------------------

The DNA sequence data generated from the partial or complete sequencing of seven (*rpoB*, *katG*, *inhA*, *pncA*, *embB*, *rpsL* and *rrs*) loci was also used to determine phylogenetic relationship among the 93 MDR-TB strains. The dendrogram based on concatenated sequence data showed 51 isolates with unique sequences, while 42 isolates grouped in 16 clusters (labeled as Cluster I to Cluster XVI) with each cluster containing 2--6 isolates (Fig. [2](#Fig2){ref-type="fig"}). The MLSA data were combined with data obtained from spoligotyping, time interval between isolation of cluster isolates with/without additional sequence data for two other (*gidB* and *rpsA*) loci and the results are presented in Table [2](#Tab2){ref-type="table"}. Based on spoligotyping data, both isolates in five clusters (Cluster V, VI, IX, XIII and XIV) were genetically unrelated strains and/or were isolated more than 2 years apart. Similarly, isolates in three other clusters were either genetically heterogeneous (Cluster 1 and IV) or were isolated 6 years apart (Cluster VII) and so were not considered epidemiologically related strains. On the contrary, isolates in eight clusters (Cluster II, III, VIII, X, XI, XII, XV and XVI) exhibited the same spoligotype and were obtained within a short time span (nearly 2 years). Further analysis of *gidB* and *rpsA* sequence data showed that all isolates in five clusters (Cluster III, VIII, XI, XV and XVI) were genotypically identical strains, highly suggestive of cross-transmission of infection among these patients or infection from a common source. Also, two of three isolates in Cluster X were identical while the two isolates in Cluster XII were very closely related. On the contrary, the two isolates in Cluster II were genotypically unrelated strains (Table [2](#Tab2){ref-type="table"}).Fig. 2The dendrogram obtained from concatenated (complete or partial) sequence data for seven (*rpoB, katG, inhA, pncA, embB, rpsL* and *rrs*) loci generated by using MEGA7 phylogenetic software with unweighted pair group method with arithmetic mean (UPGMA) settings for 93 multidrug-resistant *M. tuberculosis* isolates from Kuwait is shown. Isolates with identical sequence patterns were classified as cluster isolates and all 16 clusters (Cluster I to Cluster XVI) are marked Table 2Detailed clinical, demographic and molecular characteristics of 42 *M. tuberculosis* isolates in 16 (Cluster I to Cluster XVI) clustersCluster no.Clinical specimenIsolate no.Year of isolationPatient's nationalitySpoligotyping dataGenetic alteration detected inSITMtb family*rpoBkatGinhApncAembBrpsLrrsgidBrpsA*ISputumKM06-1532006Indian255BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.CSFKM09-222009Indian255BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.SputumKM13-372013Indian1BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.FNAKM16-062016Nepalese1BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.FNAKM17-032017Indian1BeijingTCG456TTGACG315ACCWTWTATG306GTGAAG43AGGWTN. D.N. D.IISputumKM14-582014Nepalese1BeijingTCG456TTGACG315ACCWTGTG139GCGATG306GTGAAG43AGGWTGAA92GAC + *GCA205GCGCGA212CGC*SputumKM14-692014Indian1BeijingTCG456TTGACG315ACCWTGTG139GCGATG306GTGAAG43AGGWT*GCA205GCG*WT[IIISputumKM08-5012008Kuwaiti1BeijingTCG456TTGACG315ACCWTGGT139GTTATG306GTGAAG43AGGWTGAA92GAC]{.ul} + *[GCA205GCG]{.ul}[CGA212CGC]{.ul}*[SputumKM08-5022008Kuwaiti1BeijingTCG456TTGACG315ACCWTGGT139GTTATG306GTGAAG43AGGWTGAA92GAC]{.ul} + *[GCA205GCG]{.ul}[CGA212CGC]{.ul}*[SputumKM09-2072009Indian1BeijingTCG456TTGACG315ACCWTGGT139GTTATG306GTGAAG43AGGWTGAA92GAC]{.ul} + *[GCA205GCG]{.ul}[CGA212CGC]{.ul}*IVSputumKM12-052012Ethiopian21CAS1-KiliTCG456TTGACG315ACCWTIns193A (FS) + *TCC65TCT*ATG306GTGAAG88AGGWTN. D.N. D.SputumKM12-172012Ethiopian1144T1TCG456TTGACG315ACCWTIns193A (FS) + *TCC65TCT*ATG306GTGAAG88AGGWTN. D.N. D.SputumKM15-082015Ethiopian21CAS1-KiliTCG456TTGACG315ACCWTIns193A (FS) + *TCC65TCT*ATG306GTGAAG88AGGWTN. D.N. D.VSputumKM07-3332007IndonesianOrphanN. A.TCG456TTGACG315ACCWTWTWTWTWTN. D.N. D.SputumKM10-232010Indian355EAI3-INDTCG456TTGACG315ACCWTWTWTWTWTN. D.N. D.VISputumKM07-2932007Filipino194LAM2TCG456TTGACG315ACCWTWTCAG497CGGWTWTN. D.N. D.SputumKM12-012012Filipino25CAS1-DelhiTCG456TTGACG315ACCWTWTCAG497CGGWTWTN. D.N. D.VIISputumKM09-2022009Ethiopian47H1GTC176TTCACG315ACCWTWTWTWTWTN. D.N. D.SputumKM15-172015Indian47H1GTC176TTCACG315ACCWTWTWTWTWTN. D.N. D.[VIIISputumKM14-672014Ethiopian149T3-ETHTCG456TTGACG315ACCWT]{.ul}−[11 A/GATG306ATCWTWTGGT69GATWTSputumKM15-212015Ethiopian149T3-ETHTCG456TTGACG315ACCWT]{.ul}−[11 A/GATG306ATCWTWTGGT69GATWT]{.ul}IXSputumKM07-2832007Indian26CAS1-DelhiTCG456TTGACG315ACCWT*TCC65TCT*ATG306ATAWTWTN. D.N. D.SputumKM14-682014IndianOrphanN. A.TCG456TTGACG315ACCWT*TCC65TCT*ATG306ATAWTWTN. D.N. D.SputumKM17-202017Kuwaiti1BeijingTCG456TTGACG315ACCWT−11 A/GCAG497CGGAAG43AGGWTGAA92GAC + *GCA205GCG*WTXSputumKM17-222017Kuwaiti1BeijingTCG456TTGACG315ACCWT−11 A/GCAG497CGGAAG43AGGWTGAA92GAC + *GCA205GCGCGA212CGC*SputumKM17-732017Indian1BeijingTCG456TTGACG315ACCWT−11 A/GCAG497CGGAAG43AGGWTGAA92GAC + *GCA205GCGCGA212CGC*[PusKM11-5032011Kuwaiti1BeijingTCG456TTGACG315ACCWT]{.ul}−[11 A/GGGC406GACAAG43AGGWTGAA92GAC]{.ul} + [GCA205GCG]{.ul}*[CGA212CGC]{.ul}*[SputumKM14-562014Kuwaiti1BeijingTCG456TTGACG315ACCWT]{.ul}−[11 A/GGGC406GACAAG43AGGWTGAA92GAC]{.ul} + [GCA205GCG]{.ul}*[CGA212CGC]{.ul}*[XISputumKM15-132015Kuwaiti1BeijingTCG456TTGACG315ACCWT]{.ul}−[11 A/GGGC406GACAAG43AGGWTGAA92GAC]{.ul} + [GCA205GCG]{.ul}*[CGA212CGC]{.ul}*[SputumKM15-262015Kuwaiti1BeijingTCG456TTGACG315ACCWT]{.ul}−[11 A/GGGC406GACAAG43AGGWTGAA92GAC]{.ul} + *[GCA205GCG]{.ul}[CGA212CGC]{.ul}*[SputumKM17-022015Kuwaiti1BeijingTCG456TTGACG315ACCWT]{.ul}−[11 A/GGGC406GACAAG43AGGWTGAA92GAC]{.ul} + *[GCA205GCG]{.ul}[CGA212CGC]{.ul}*[SputumKM17-692017Kuwaiti1BeijingTCG456TTGACG315ACCWT]{.ul}−[11 A/GGGC406GACAAG43AGGWTGAA92GAC]{.ul} + *[GCA205GCG]{.ul}[CGA212CGC]{.ul}*XIISputumKM16-322016Egyptian19EAI2-ManilaCAC451TACACG315ACC−15 C/TGAA37AAA*CTG355CTA* + GAG378GCGWTWT*GTG110GTT* + *GCA205GCG*WTSputumKM17-012017Filipino19EAI2-ManilaCAC451TACACG315ACC−15 C/TGAA37AAA*CTG355CTA* + GAG378GCGWTWTCTC95TTC + *GTG110GTT* + *GCA205GCG*WTXIIIPusKM07-2972007IndianOrphanN. A.CAC451GACWT−15 C/T*TCC65TCG* + Ins 453T (FS)ATG306CTGWTWTN. D.N. D.FNAKM11-5022015Indian3361T1CAC451GACWT−15 C/T*TCC65TCG* + Ins 453T (FS)ATG306CTGWTWTN. D.N. D.XIVSputumKM06-482006Egyptian53T1TCG456TTGWT−15 C/TWTWTWTWTN. D.N. D.TissueKM06-2772006Filipino19EAI2-ManilaTCG456TTGWT−15 C/TWTWTWTWTN. D.N. D.[XVSputumKM16-332016Indian8EAI3/EAI5CAC451TACACG315ACCWTCTG35CCGATG306GTG]{.ul} + [GAG378GCGAAG43AGGWT]{.ul}*[GTG110GTT]{.ul}* + *[GCA205GCG]{.ul}*[WTSputumKM17-062017Filipino8EAI3/EAI5CAC451TACACG315ACCWTCTG35CCGATG306GTG]{.ul} + [GAG378GCGAAG43AGGWT]{.ul}*[GTG110GTT]{.ul}* + *[GCA205GCG]{.ul}*[WTXVISputumKM07-2312007IndianOrphan]{.ul}^a^[CAS1-DelhiATG440ATA]{.ul} + [GAC441TACACG315ACCWT]{.ul}*[TCC65TCT]{.ul}*[GGC406TGCWTWT]{.ul}*[GCA205GCG]{.ul}* + [Del 350G (FS)WTSputumKM07-2522007SyrianOrphan]{.ul}^a^[CAS1-DelhiATG440ATA]{.ul} + [GAC441TACACG315ACCWT]{.ul}*[TCC65TCT]{.ul}*[GGC406TGCWTWT]{.ul}*[GCA205GCG]{.ul}* + [Del 350G (FS)WT]{.ul}Clusters containing MDR-TB strains with identical patterns and isolated within a period of nearly 2 years are underlined. Synonymous mutations are italicizedN. A., not applicable; N. D., not done; CSF, cerebrospinal fluid; FNA, fine needle aspirate; SIT, shared international type; Mtb family, *M. tuberculosis* family; WT, wild-type sequence; Ins, insertion mutation; (FS), frame shift mutation^a^Both isolates displayed identical spoligotyping pattern
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The TB control in low incidence settings involves molecular fingerprinting of *M. tuberculosis* isolates to detect unsuspected outbreaks which also indicates possible epidemiological links between TB patients and differentiates reactivated TB from newly acquired infection \[[@CR1], [@CR33]\]. Molecular fingerprinting techniques for *M. tuberculosis* have evolved from IS*6110*-based restriction fragment length polymorphism to mycobacterial interspersed repetitive unit-variable-number tandem repeat (MIRU-VNTR) typing with/without spoligotyping and more recently, to whole genome sequence (WGS) comparisons \[[@CR34]--[@CR38]\]. Since whole genome comparisons are not yet standardized, core genome multi-locus sequence typing (cgMLST) has been developed to facilitate high-resolution fingerprinting of clinical *M. tuberculosis* isolates to trace recent transmission of infections \[[@CR38], [@CR39]\]. Genomic sequence-based scanning for drug resistance-associated mutations has also been shown to be nearly comparable to MIRU-VNTR typing \[[@CR40]\].

More than 80% of all TB cases and \> 95% of DR-TB and MDR-TB cases in Kuwait occur among expatriates \[[@CR14]--[@CR19]\]. Unexpectedly, several cases of MDR-TB were diagnosed among Kuwaiti subjects during recent (2014--2017) years, and it was not known whether any of these also resulted from cross-transmission of infection or infection from a common source. In this retrospective study, we performed molecular characterization of all available MDR-TB strains collected over a 12-year period to catalog mutations conferring resistance to first-line drugs to determine the feasibility of using commercial molecular methods for rapid diagnosis of MDR-TB in Kuwait. We also employed sequence-based scanning of seven loci to determine relatedness among MDR-TB strains. Further fingerprinting by spoligotyping combined with sequence data for additional loci known to display phylogenetic polymorphisms and other relevant epidemiological information were used to track transmission of MDR-TB among TB patients in Kuwait.

Our data showed that 91 of 93 (97.8%) MDR-TB strains contained a mutation in *rpoB* hot spot region and S456L mutation was most common, found in 66 of 93 (71%) isolates which is consistent with published reports from different geographical settings \[[@CR7], [@CR41]--[@CR43]\]. Only three MDR-TB strains contained double *rpoB* mutations which is also in line with limited previous exposure of TB patients in Kuwait to anti-TB drugs \[[@CR41], [@CR43]\]. Similarly, mutations at *katG315* and *inhA*-RR were detected in 80 of 93 (86.0%) and 16 of 93 (17.2%) MDR-TB strains, respectively, which are consistent with the reported worldwide occurrence of these mutations \[[@CR7], [@CR41]--[@CR43]\]. Altogether, 91 of 93 (98%) MDR-TB strains contained a mutation at *katG315* and/or *inhA*-RR. Of the remaining two isolates, one isolate contained S94A mutation in *inhA* which is known to confer resistance to isoniazid \[[@CR44]\]. Taken together, our data show that rapid molecular diagnostic tests (such as GenoType MTBDR*plus* assay and targeted PCR sequencing) that interrogate *rpoB* hot spot region and *katG315* + *inhA*-RR will have a sensitivity of 98% for rifampicin resistance detection, 98% for isoniazid resistance detection and 96% for MDR-TB in Kuwait with 100% specificity. The higher occurrence of S456L mutation in *rpoB* and S315T mutation in *katG* in our MDR-TB strains is also consistent with the low fitness cost associated with these specific mutations \[[@CR45]\].

Ethambutol, a first-line drug, may be included in treatment regimens for MDR-TB provided the isolate is susceptible to this drug. Streptomycin is no longer considered a first-line drug and is usually not used in treatment regimens due to high rates of resistance in *M. tuberculosis* isolates globally \[[@CR5], [@CR6], [@CR46]\]. Resistance-conferring mutations in *rpsL* and/or *rrs* gene was detected in majority (49 of 59, 83%) of streptomycin-resistant but not in any streptomycin-susceptible MDR-TB strain, while mutations in *embB* gene were detected in both ethambutol-resistant and ethambutol-susceptible MDR-TB strains, as described in our previous studies \[[@CR23], [@CR28]\].

Pyrazinamide is used for the treatment of both drug-susceptible TB and MDR-TB \[[@CR5], [@CR6], [@CR46]\]. The in vitro susceptibility testing of pyrazinamide is technically challenging and often unreliable due to well-known problems (size of the test inoculum, no growth of some strains in drug-free tube under acidic conditions etc.) recognized in previous studies \[[@CR47]--[@CR49]\]. Phenotypic DST results for pyrazinamide were available for only 47 of 93 MDR-TB strains, while the remaining 46 isolates failed to grow at lower pH. No *pncA* mutation was detected in 50 pansusceptible strains. Analysis of 93 MDR-TB strains showed that 30 of 36 MDR-TB strains phenotypically resistant to pyrazinamide and 23 of 46 isolates for which DST data for pyrazinamide was not available contained a mutation in *pncA* while all 11 MDR-TB strains phenotypically susceptible to pyrazinamide contained wild-type sequence for *pncA*. The −11 A/G mutation in the regulatory region was most common which is known to reduce the expression of pyrazinamidase \[[@CR29], [@CR50]\]. Seven isolates contained insertion/deletion frame shift mutations which will also lead to an inactive pyrazinamidase. Non-synonymous, high/very high confidence resistance mutations with/without additional mutation in regulatory region were observed in 29 isolates which have also been detected in other studies \[[@CR7], [@CR29], [@CR49]\]. Our data showing a resistance-conferring mutation in 30 of 36 (83%) of pyrazinamide-resistant and in none of 11 pyrazinamide-susceptible MDR-TB strains support previous observations that *pncA* mutations may be used as a surrogate marker of pyrazinamide resistance in *M. tuberculosis* \[[@CR7], [@CR29], [@CR41], [@CR50], [@CR51]\].

Spoligotyping data showed that Beijing genotype was most common, shared by 32 of 93 (34%) MDR-TB strains in Kuwait which is expected since this family is known to be strongly associated with multidrug resistance \[[@CR52]\]. The occurrence of this genotype was significantly higher in isolates resistant to all four SIRE drugs. The Beijing genotype is also common among drug-resistant/MDR-TB strains from neighboring countries \[[@CR53], [@CR54]\]. The occurrence of nine unique (orphan) spoligotyping patterns not reported previously reflects genetic diversity among MDR-TB strains in Kuwait which is not surprising since 81 of 93 (87%) MDR-TB strains were obtained from expatriate patients originating from 11 different countries who were TB-free at the time of their entry into Kuwait, thereby implying that most of these cases likely represent reactivation TB.

The phylogenetic tree generated from concatenated sequence data from partial or complete sequencing of seven (*rpoB*, *katG*, *inhA*, *pncA*, *embB*, *rpsL* and *rrs*) loci identified 42 isolates in 16 clusters (labeled as Cluster I to Cluster XVI) which could likely represent cross-transmission of infection or infection from a common source. This approach has previously been shown to be nearly comparable to the 24-loci-based MIRU-VNTR typing \[[@CR40], [@CR55], [@CR56]\]. The first case in each cluster was considered as the 'index case' and an arbitrary window period of nearly 2 years was used to define epidemiologically related strains since reactivation of latent infection usually occurs during the first 2 years (even though this period of latency could also be much longer) after infection with *M. tuberculosis* \[[@CR2]\]. The two isolates in five clusters (Cluster V, VI, IX, XIII and XIV) were genetically unrelated strains by spoligotyping. Similarly, at least some of the isolates in Cluster I and Cluster IV were genetically unrelated strains by spoligotyping while the two isolates in Cluster VII were separated by a much longer time (6 years) than is normally expected. However, isolates in eight clusters (Cluster II, III, VIII, X, XI, XII, XV and XVI) belonged to the same spoligotype and were obtained within a short time span (nearly 2 years) from each other.

Further analysis of *gidB* and *rpsA* carried out for selected cluster isolates showed that all isolates in five clusters (Cluster III, VIII, XI, XV and XVI) were genotypically identical strains, highly suggestive of cross-transmission of infection among these patients or infection from a common source. Also, two of three isolates in Cluster X were identical. The two isolates in Cluster XII were also very closely related, with the second isolate (KM17-01) displaying an additional mutation (L95F) in *gidB* which is considered as a hot spot for mutations in the *M. tuberculosis* genome \[[@CR21], [@CR57]\]. In a recent study, Appelgren et al. \[[@CR58]\] investigated transmission of pre-XDR *M. tuberculosis* infection in a healthcare worker in France by gene-scanning of multiple loci involved in conferring resistance to anti-TB drugs and MIRU-VNTR typing. The authors concluded that the healthcare worker had contacted the infection from a patient that displayed nearly identical mutation and MIRU-VNTR patterns. More elaborate sequence comparisons derived from WGS or cgMLST have also identified transmission of infection in low-TB-incidence settings \[[@CR59]--[@CR61]\].

Due to the retrospective nature of our study, investigations to confirm the transmission of infection and identification of epidemiological links and contact tracing were delayed and/or were unsuccessful as most of the TB patients, being expatriate subjects, had left the country, after initial treatment objective (sputum smear-negative status) was achieved. The epidemiological investigations for Kuwaiti patients in Cluster XI were also incomplete as the first case did not appear to be the index case as this patient had extra-pulmonary TB and no obvious connection was apparent between the six subjects during contact tracing. It is probable that the index case was an expatriate patient who is not included in this study and had left the country before the cases described here were characterized. Even WGS comparisons sometimes fail to identify transmission of TB in a setting with a high proportion of migrant (expatriate) cases \[[@CR62]\].

Our study has a few limitations. (i) Due to retrospective nature of the study, all MDR-TB isolates collected during the study period were not included and epidemiological investigations and contact tracing were delayed. Since expatriate TB patients are sent back to their respective country after initial treatment objective (sputum smear-negative status) was achieved, some patients could not be contacted as they had left the country. (ii) Molecular fingerprinting of the isolates, particularly cluster isolates, was not performed by MIRU-VNTR typing or by more discriminatory WGS or cgMLST.

Conclusion {#Sec15}
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In conclusion, our data show that rapid molecular diagnostic tests that interrogate hot spot region of *rpoB* and *katG315* + *inhA*-RR will have a sensitivity of 98% for rifampicin resistance detection, 98% for isoniazid resistance detection and 96% for MDR-TB in Kuwait. Our data also showed that 53 of 93 (57%) MDR-TB strains contain *pncA* mutations and are thus additionally resistant to pyrazinamide. Our study provides first insight into molecular epidemiology of MDR-TB in Kuwait and identified at least five clusters of local transmission of MDR-TB involving 2--6 subjects which had escaped detection by routine surveillance studies. Prospective detection of resistance-conferring mutations in major gene targets and molecular fingerprinting studies can identify possible cases of local transmission of MDR-TB in low MDR-TB settings which can then be investigated for epidemiological linkage and contact tracing to arrest further transmission of infection.
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**Additional file 1: Table S1.** DNA sequences of oligonucleotide primers used for the amplification of various gene targets and the size of amplicon obtained for each primer pair. **Additional file 2: Table S2.** DNA sequences of oligonucleotide primers used for the sequencing of various gene targets.

DST

:   drug susceptibility testing

DR-TB

:   drug-resistant tuberculosis

*inhA*-RR

:   *inhA*-regulatory region

*katG315*

:   *katG* codon 315

MDR-TB

:   multidrug-resistant tuberculosis

MGIT

:   mycobacteria growth indicator tube

MLSA

:   multi-locus sequence analysis

cgMLST

:   core genome multi-locus sequence typing

MIRU-VNTR

:   mycobacterial interspersed repetitive unit-variable-number tandem repeat

PZA

:   pyrazinamide

SIT

:   shared international type

UPGMA

:   unweighted pair group method with arithmetic averages

XDR-TB

:   extensively drug-resistant tuberculosis

WGS

:   whole genome sequencing

WHO

:   World Health Organization

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1186/s40001-019-0397-2.

None.

NMA, SA, EM conceived and designed the study. NMA helped in collection of data. NMA, SA, EM analyzed the data. NMA, SA, EM contributed to manuscript preparation. All authors read and approved the final manuscript.

The study was supported by Kuwait University Research Sector Grant YM08/14 and Research Core Facility Grant SRUL 02/13. The funding body had no role in the design of the study, collection, analysis and interpretation of data or in the writing of the manuscript.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

The study was approved and the need for written informed consent from patients was waived by the Health Sciences Center Ethics Committee, Faculty of Medicine, Kuwait University (Approval No. VDR/EC/2 dated 09-02-2015) and the Ministry of Health, Kuwait.

Not applicable.

The authors declare that they have no competing interests.
